Compare SMID & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | KZIA |
|---|---|---|
| Founded | 1960 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 154.9M |
| IPO Year | 1996 | 2002 |
| Metric | SMID | KZIA |
|---|---|---|
| Price | $28.36 | $12.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 11.1K | ★ 199.6K |
| Earning Date | 04-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $93,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $111.64 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.60 | $4.86 |
| 52 Week High | $43.62 | $17.40 |
| Indicator | SMID | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | N/A |
| Support Level | $27.61 | N/A |
| Resistance Level | $31.47 | N/A |
| Average True Range (ATR) | 1.55 | 0.00 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 25.64 | 0.00 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.